Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 to 75

Comparing ticagrelor and prasugrel for heart disease treatment

Official title: Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors: Pharmadodynamic Comparison Between Prasugrel and Ticagrelor Monotherapy. The Switching Antiplatelet -7 (SWAP-7) Study

Run by University of Florida · NCT06691191 · Data updated 2026-11-12

This study is testing whether ticagrelor or prasugrel is better at preventing bleeding and heart issues in patients with heart disease who have already been on another type of treatment.

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years to 75 Years
SexAll
Enrollment48 (estimated)
SponsorUniversity of Florida
Academic / other
Locations1 site (Jacksonville, Florida)
StatusRecruiting
StartedJanuary 8, 2025
Main results expectedAugust 31, 2026
Study endsDecember 31, 2026
Registry record updatedFebruary 5, 2026
Trial IDNCT06691191 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 to 75 who have been on dual antiplatelet therapy for at least 90 days after a percutaneous coronary intervention.

Probably not a fit

Patients with a history of stent thrombosis, recent PCI, or those over 75 years old may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to compare the effectiveness of ticagrelor and prasugrel as single antiplatelet therapies after patients have undergone dual antiplatelet therapy for coronary artery disease. It will evaluate the pharmacodynamic profiles of both medications to determine if they are comparable in reducing bleeding events without increasing the risk of heart-related complications. The study will involve patients aged 18 to 75 who have been on dual antiplatelet therapy for at least 90 days following a percutaneous coronary intervention. Participants will be randomly assigned to receive either ticagrelor or prasugrel for the duration of the study.

Why it matters

Potential benefit: If successful, this study could help identify a safer and more effective antiplatelet therapy for patients with coronary artery disease.

How similar studies have gone: Previous studies have shown success with similar approaches, particularly with ticagrelor monotherapy demonstrating reduced bleeding events without increasing ischemic risk.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion criteria:

1. Patients on DAPT with aspirin plus prasugrel 10 mg or ticagrelor 90 mg bid as per standard of care at least 90 days after PCI.
2. Age between 18 and 75 years old
3. Able to provide written informed consent

Exclusion criteria:

1. Prior history of stent thrombosis
2. PCI within 90 days.
3. History of stroke/TIA
4. Age \> 75 years old
5. Weight \< 60 kg
6. History of intracranial hemorrhage
7. On treatment with any oral anticoagulant or chronic low-molecular-weight heparin (at venous thrombosis treatment, not for prophylaxis)
8. Patients with known coagulation disorders
9. Known severe hepatic impairment
10. Hypersensitivity to prasugrel or ticagrelor
11. Pregnant and breastfeeding persons \[persons of childbearing age must use reliable birth control (i.e., oral contraceptives) while participating in the study\]. If the potential subject is a person of childbearing potential, a pregnancy test will be done. If the subject is pregnant, participation in this study will end.

Where it's running

  • University of Florida Jacksonville
    Jacksonville, Florida, United States
    Recruiting

Study contacts

  • Principal investigator: Francesco Franchi, MD — University of Florida College of Medicine Jacksonville
  • Study coordinator: Francesco Franchi, MD
  • Email: francesco.franchi@jax.ufl.edu
  • Phone: 9042445515

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.